Physical activity associated with less chemo-induced peripheral neuropathy
the ONA take:
Meeting the physical activity guideline was associated with less chemotherapy-induced peripheral neuropathy (CIPN)-like symptoms and a higher health-related quality of life (HRQoL) regardless of treatment with chemotherapy among colorectal cancer survivors, a new study published in the Journal of Cancer Survivorship: Research and Practice has shown.
For the study, researchers in the Netherlands sought to investigate whether there is an association between physical activity, CIPN, and HRQoL among colorectal cancer survivors.
Researchers analyzed data from a Dutch prospective population-based survey among colorectal cancer survivors diagnosed between 2000 and 2009.
Of those, 83% completed the the EORTC QLQ-C30 and the EORTC QLQ-CIPN20 questionnaires. Of those, 31% were treated with chemotherapy.
Results showed that treatment with chemotherapy was associated with a higher number of patients reporting CIPN symptoms regardless of physical activity.
Researchers found that patients treated with chemotherapy who did not complete 150 minutes of moderate to vigorous physical activity a week experienced more CIPN. The study also showed that patients not treated with chemotherapy reported CIPN-like symptoms, especially when they did not complete the 150 minutes/week of exercise.
The findings suggest that health care professionals and colorectal cancer survivors should be aware of the importance of physical activity.
Meeting the physical activity guideline associated with less chemotherapy-induced peripheral neuropathy in colorectal cancer survivors.
Sign Up for Free e-newsletters
- Fluorouracil Associated With Reduced Surgery for Squamous Cell Carcinoma
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Comparison of Survival Outcomes Between Radical Hysterectomy and Definitive Radiochemotherapy in Stage IB1 and IIA1 Cervical Cancer
- Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
- Adherence to Skin Cancer Screening Guidelines Beneficial in Management SCC in SOTRs
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|